Use of a superactive luteinizing hormone releasing hormone (LHRH) agonist in the treatment of menorrhagia.
A luteinizing hormone releasing hormone agonist, D-Ser(But)6des Gly10-LHRH ethylamide, was administered intranasally to four women with unexplained ovulatory menorrhagia. Dramatic reductions in excessive menstrual blood losses were induced without significant side-effects, although the pattern of loss returned to pretreatment levels within 2 months of ceasing therapy.
D000328:Adult; D002064:Buserelin / Q000627:therapeutic use*; D003404:Creatinine / Q000652:urine; D004967:Estrogens / Q000652:urine; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008595:Menorrhagia / Q000188:drug therapy* / Q000503:physiopathology / Q000652:urine; D008598:Menstruation; D010060:Ovulation / Q000187:drug effects*
D004967:Estrogens; D006454:Hemoglobins; D003404:Creatinine; D002064:Buserelin